FTSE MIB
33.987,67 -118,34 (-0,35%) Dow Jones
39.375,87 +67,87 (+0,17%) Nasdaq
18.352,76 +164,46 (+0,90%) Nikkei 225
40.912,37 -1,28 (-0,00%) Petrolio
83,44 -0,44 (-0,52%) Bitcoin EUR
53.451,21 +1.412,14 (+2,71%)
MDT Feb 2025 87.500 call
| Chiusura precedente | 2,1900 |
| Aperto | 2,1900 |
| Denaro | 1,2100 |
| Domanda | 2,0100 |
| Prezzo d'esercizio | 87,50 |
| Scadenza | 2025-02-21 |
| Min-Max giorno | 2,1900 - 2,1900 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 16 |
GlobeNewswireGentherm Announces Dr. Ken Washington as New Independent Director
NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company’s Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE: MDT),
GlobeNewswireOrchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation (“AVIM”) therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the en
